Crestline Management, L.P. — Q1 2026 13F-HR

← Crestline Management, L.P.

Q1 2026 · 13F-HR

Crestline Management, L.P.holdings as filed

Filed 2026-05-15 · accession 0001315863-26-000412

$46.3M

Reported value

Positions

2026-03-31

Period end

View analyzed profile →PRO

The Brief · Crestline Management, L.P. · Q1 2026

AI · grounded in 13F

Crestline Management, L.P. reduced its position in SANA by 38.102%. The fund also trimmed its holding in DNLI by 21.3468%. Conversely, the manager slightly accumulated shares of EGHT by 0.0273%.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
24823R105	DNLI	DENALI THERAPEUTICS INC	$42.4M	91.7%	2,210,732	Common	SOLE
799566104	SANA	SANA BIOTECHNOLOGY INC	$2.2M	4.70%	755,736	Common	SOLE
282914100	EGHT	8X8 INC NEW	$1.6M	3.56%	990,850	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.